Loss of detectable antibody to hepatitis B surface antigen in immunized patients with hemophilia but without human immunodeficiency virus infection.
We investigated the loss of detectable antibody directed against the hepatitis B surface antigen after immunization with hepatitis B vaccine in 55 patients who were seronegative for the human immunodeficiency virus and had hemophilia. Twenty percent of patients lost detectable antibody at a mean of 4.6 years after completion of immunization. Monitoring of hepatitis B serostatus or routine revaccination may be necessary.
Division of Hematology, Children's Hospital of Philadelphia, PA 19104.
J M
JM
Maris
R B
RB
Butler
A R
AR
Cohen
D002648:Child; D002675:Child, Preschool; D018023:HIV Seronegativity / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006467:Hemophilia A / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007223:Infant; D015143:Philadelphia; D012189:Retrospective Studies; D013997:Time Factors
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines